20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Moderna Inc (NASDAQ:MRNA) is gearing up to halve the dose of its COVID-19 vaccine so that it can also be used to combat variants and inoculate children.
- It has entered into a deal with Lonza Group (OTC:LZAGF) for a new drug substance production line in Geleen, Netherlands, which will have the capacity to make ingredients for up to 300 million doses annually at 50 micrograms per dose.
- The new agreement with Lonza will increase drug substance production in Europe by the fourth quarter of 2021.
- Currently, Moderna has been delivering an approved 100-microgram dose to date.
- It said early booster shot data for a 50-microgram version showed it helped protect against emerging virus variants.
- Combined with a previous deal with Spain's Rovi, Moderna's pact with Lonza brings 50-microgram production in Europe to up to 600 million doses annually, with the capacity due to come online in 2021.
- Price Action: MRNA shares closed at $184.66 on Tuesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!